From the FDA, we still hear mostly thunderous silenceBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h3763 (Published 14 July 2015) Cite this as: BMJ 2015;351:h3763
- Erick H Turner, physician-researcher1
- 1Oregon Health and Science University, Portland, OR 97239, USA
Lurie and colleagues’ comparison of FDA letters not approving applications for new drugs and associated public announcements from sponsors provides a valuable but rare peek behind the Food and Drug Administration’s “iron curtain.” The discussion section begins, “our analysis found that the FDA’s reasons for not approving marketing applications for new molecular entities are not being fully conveyed to the public.”1 On the basis of the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial